CTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in Stock
CTI BioPharma Corp. (NASDAQ:CTIC) Director Richard L. Love sold 14,600 shares of CTI BioPharma Corp. stock in a transaction on Friday, September 29th. The stock was sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the transaction, the director now directly owns 84,318 shares in the company, valued at $270,660.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.25 on Thursday. The firm has a 50-day moving average of $3.26 and a 200 day moving average of $3.65. CTI BioPharma Corp. has a 12-month low of $0.36 and a 12-month high of $6.48. The stock’s market capitalization is $103.11 million.
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million during the quarter. On average, analysts predict that CTI BioPharma Corp. will post ($1.26) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in the stock. Stonepine Capital Management LLC bought a new stake in shares of CTI BioPharma Corp. during the 2nd quarter worth $7,561,000. WASHINGTON TRUST Co bought a new stake in shares of CTI BioPharma Corp. during the 2nd quarter worth $104,000. Finally, Segantii Capital Management Ltd bought a new stake in shares of CTI BioPharma Corp. during the 1st quarter worth $102,000. Institutional investors and hedge funds own 42.87% of the company’s stock.
Separately, Jefferies Group LLC started coverage on shares of CTI BioPharma Corp. in a report on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target on the stock.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.